Alejandro Falcón González

6PUBLICATIONS
91CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 06, 2026
UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.

Ana Gil-Torralvo, M Ángeles Domínguez-Cejudo, Sonia Molina-Pinelo

|Jul 09, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Adrian G Sacher, Wilson H Miller, Manish R Patel

|Mar 17, 2025
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

Johann S de Bono, Anja Williams, Ignacio Melero

|Jul 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.

Hans Gelderblom, Albiruni A Razak, Matthew H Taylor

|Mar 28, 2024
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study.

Alejandro Falcón González, Josefina Cruz Jurado, Elisenda Llabrés Valenti

|Dec 05, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.

Jayesh Desai, Guzman Alonso, Se Hyun Kim

Pageof 1